Souhaitez-vous accéder aux communiqués récents ?

Awaiting FDA clinical hold letter on MAGNITUDE and MAGNITUDE-2 clinical trials of nex-zPresenting longer-term Phase 1 clinical data of nex-z for ATTR-CM on November 10 at AHA 2025; previously...

LithiX™ HC-IVL is a novel lithotripsy system designed to facilitate treatment of heart disease exacerbated by the presence of calcium within coronary artery plaques MY-IVL study enrolled 102 real...

Dallas, TX, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The North Texas Food Bank (NTFB) unveiled this week its newly cobranded container pantry, sponsored by the American Heart Association and Medical City...

New analysis confirms reductions in blood pressure and albuminuria by aprocitentan in patients with true resistant hypertension and high cardiovascular risk – including chronic kidney disease ...

Oral Presentation on Saturday to Highlight Interim Safety and Efficacy Results from the MyPEAK™-1 Phase 1b/2a Clinical Trial in Adults with MYBPC3-Associated Hypertrophic Cardiomyopathy Second...

Dublin, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The "Artificial Intelligence (AI)-Generated Voice Therapy Exercise Market Report 2025" report has been added to ResearchAndMarkets.com's offering.The...

THE WOODLANDS, Texas, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX) today announced that data from three studies of sotagliflozin will be presented during upcoming...

KIRKLAND, Wash., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced its participation in...

Fabhalta and Vanrafia Phase III analyses, Fabhalta real-world treatment pattern data, and zigakibart Phase I/II trial showcase strength of IgA nephropathy (IgAN) portfolioC3 glomerulopathy (C3G)...

PALO ALTO, Calif. and NEEDHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Bitterroot Bio, a leader in developing innovative medicines in the field of cardio-immunology, announced today that the...